New treatment approach for triple negative breast cancer using targeted siRNA delivery
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy
This study is testing a new way to deliver a special treatment directly to tumors in patients with triple negative breast cancer, making it easier for the medicine to reach the cancer and potentially improve how well it works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-10925327 on NIH RePORTER |
What this research studies
This research focuses on developing a novel method to deliver small interfering RNA (siRNA) specifically to tumors in patients with triple negative breast cancer. By modifying siRNA molecules to enhance their ability to penetrate tumor tissues, the study aims to overcome existing barriers that limit the effectiveness of RNA-based therapies. The approach involves using a special chemical modification that allows siRNA to bind to albumin in the bloodstream, which helps it reach the tumor more effectively. This could lead to more effective treatments for patients with hard-to-target cancer drivers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who may benefit from innovative therapeutic approaches.
Not a fit: Patients with other types of breast cancer or those who do not have access to the specific treatment protocols may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with triple negative breast cancer, potentially improving their outcomes.
How similar studies have performed: Previous research has shown promise in using similar siRNA delivery methods, indicating potential for success in this novel approach.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Duvall, Craig Lewis — Vanderbilt University
- Study coordinator: Duvall, Craig Lewis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.